Search Results - "de Leval, X"

Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1) by Mouithys-Mickalad, Ange, Deby-Dupont, Ginette, Dogne, Jean-Michel, de Leval, Xavier, Kohnen, Stephan, Navet, Rachel, Sluse, Francis, Hoebeke, Maryse, Pirotte, Bernard, Lamy, Maurice

“…Chronic inflammation through foam cells and macrophages is important in atherosclerosis development, and can be considered as therapeutic targets…”
Get full text

Recent advances in inducible cyclooxygenase (COX-2) inhibition by de Leval, X, Delarge, J, Somers, F, de Tullio, P, Henrotin, Y, Pirotte, B, Dogné, J M

“…Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but…”
Get more information

Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation by de Leval, X, Benoit, V, Delarge, J, Julémont, F, Masereel, B, Pirotte, B, Merville, M.-P, David, J.-L, Dogné, J.-M

“…Evidence exists that a large number of tumor cells such as osteosarcoma cells stimulate platelet aggregation, which can be an early step in the metastatic…”
Get full text

In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators by Henrotin, Y, de Leval, X, Mathy-Hartet, M, Mouithys-Mickalad, A, Deby-Dupont, G, Dogné, J M, Delarge, J, Reginster, J Y

“…To investigate the mechanisms of action underlying the anti-inflammatory action of aceclofenac in vivo, we studied in vitro the effect of aceclofenac and its…”
Get full text

Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function by Dogné, J.-M, de Leval, X, Kolh, P, Sanna, V, Rolin, S, Michaux, C, Mauer, M, David, J.-L, Masereel, B, Pirotte, B

“…The aim of this work was to evaluate the effects of BM-567 ( N-pentyl- N′-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, on both…”
Get full text

N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: Cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism by Renard, Jean-François, Lecomte, Frédéric, Hubert, Philippe, de Leval, Xavier, Pirotte, Bernard

“…Nimesulide, a COX-2 preferential inhibitor with a favorable gastric and cardiovascular safety profile, was responsible for some cases of acute liver failure…”
Get full text

Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function by Dogné, J.M., de Leval, X., Neven, P., Rolin, S., Wauters, J., David, J.-L., Delarge, J., Massereel, B.

“…In this study we examined the thromboxane A2(TXA2) receptor antagonist property of BM-531 (N-tert -butyl- N′-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea),…”
Get full text

Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood by de Leval, X., Delarge, J., Devel, P., Neven, P., Michaux, C., Masereel, B., Pirotte, B., David, J.-L., Henrotin, Y., Dogné, J.-M.

“…Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances involved in several physiological processes and also in…”
Get full text

Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study by de Leval, X, Dogné, J M, Neven, P, Labasse, A, Delarge, J, Reginster, J Y, Henrotin, Y

“…Evidence of the existence of two forms of cyclooxygenases and the clinical relevance of COX-2 inhibition led to the development of COX-2 selective NSAIDs. In…”
Get more information

BM 144: an original thromboxane A2 receptor antagonist derived from torasemide by Dogné, J M, Neven, P, Damas, J, Fontaine, J, Rolin, S, De Leval, X, Delarge, J, Masereel, B

“…Torasemide, a new sulfonylurea high ceiling loop diuretic, has been demonstrated to induce a concentration dependent relaxation of canine coronary…”
Get more information

Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method by Michaux, Catherine, de Leval, Xavier, Julémont, Fabien, Dogné, Jean-Michel, Pirotte, Bernard, Durant, François

“…A four-point pharmacophore of COX-2 selective inhibitors was derived from a training set of 16 compounds, using the Catalyst program. It consists of a H bond…”
Get full text

New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators by de Leval, Xavier, Hanson, Julien, David, Jean-Louis, Masereel, Bernard, Pirotte, Bernard, Dogné, Jean-Michel

“…Prostacyclin (PGI(2)) is a potent endogenous inhibitor of platelet function and possesses a strong vasodilator effect. Furthermore, prostacyclin is currently…”
Get more information

Increased Expression of Bone Sialoprotein in Bone Metastases Compared with Visceral Metastases in Human Breast and Prostate Cancers by Waltregny, David, Bellahcène, Akeila, De Leval, Xavier, Florkin, Benoǐt, Weidle, Ulrich, Castronovo, Vincent

“…The recent demonstration that bone sialoprotein (BSP) is expressed in osteotropic cancers suggests that this bone matrix protein might be implicated in the…”
Get full text

Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2 by BENOIT, Valérie, RELIC, Biserka, DE LEVAL, Xavier, CHARIOT, Alain, MERVILLE, Marie-Paule, BOURS, Vincent

“…The oncoprotein HER-2/neu is a prosurvival factor and its overexpression has been correlated with adverse prognosis in breast cancers. High levels of the…”
Get full text

New trends in dual 5-LOX/COX inhibition by Leval, Xavier de, Julemont, Fabien, Delarge, Jacques, Pirotte, Bernard, Dogne, Jean-Michel

“…Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. The interest of developing such compounds is supported by a large number…”
Get more information

New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators by Dogné, Jean-Michel, de Leval, Xavier, Hanson, Julien, Frederich, Michel, Lambermont, Bernard, Ghuysen, Alexandre, Casini, Angela, Masereel, Bernard, Ruan, Ke-He, Pirotte, Bernard, Kolh, Philippe

“…The pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and thromboembolic diseases can be related to arachidonic acid (AA) metabolites. One of…”
Get more information

Design, Synthesis, and Pharmacological Evaluation of Pyridinic Analogues of Nimesulide as Cyclooxygenase-2 Selective Inhibitors by Julémont, Fabien, de Leval, Xavier, Michaux, Catherine, Renard, Jean-François, Winum, Jean-Yves, Montero, Jean-Louis, Damas, Jacques, Dogné, Jean-Michel, Pirotte, Bernard

“…In this study, we report the synthesis and pharmacological evaluation of original pyridinic sulfonamides related to nimesulide, a cyclooxygenase-2 (COX-2)…”
Get full text

Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time by Dogné, Jean-Michel, Hanson, Julien, de Leval, Xavier, Kolh, Philippe, Tchana-Sato, Vincent, de Leval, Laurence, Rolin, Stéphanie, Ghuysen, Alexandre, Segers, Patrick, Lambermont, Bernard, Masereel, Bernard, Pirotte, Bernard

“…The present study was undertaken to characterize the antiplatelet and antithrombotic effects of BM-573…”
Get more information

Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531 by Dogné, J M, Rolin, S, de Leval, X, Benoit, P, Neven, P, Delarge, J, Kolh, P, Damas, J, David, J L, Masereel, B

“…BM-531 (N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, is a novel noncarboxylic thromboxane receptor antagonist…”
Get more information

Recent advances in antiplatelet agents by Dogne, Jean-Michel, de Leval, Xavier, Benoit, Patricia, Delarge, Jacques, Masereel, Bernard, David, Jean-Louis

“…Platelet aggregation plays a key role in the pathogenesis of thromboembolic diseases such as myocardial infarction, stroke, unstable angina and peripheral…”
Get more information